FDA to ease testing rules to speed biosimilar approvals

March 9 (Reuters) - The U.S. Food and Drug Administration plans to ease testing requirements for companies developing biosimilar drugs, Bloomberg News reported, citing an agency official and internal documents. The FDA is expected to issue draft guidance as soon as Monday that would reduce the need for certain studies used to show that biosimilar medicines match the brand-name treatments they are